A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea

V M Coyle, D Lungulescu, C Toganel, A Niculescu, S Pop, T Ciuleanu, C Cebotaru, J Devane, M Martin, R H Wilson

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Background: AGI004 is a controlled-release transdermal patch preparation of mecamylamine. We conducted a randomised placebo-controlled phase II study of two dose levels of AGI004 in chemotherapy-induced diarrhoea (CID).

Methods: Adult patients receiving chemotherapy who had experienced diarrhoea (NCI grade 1-2) during previous cycles of chemotherapy were eligible. In all, 64 patients were randomised to receive AGI004 4mg then 8mg per 24 h transdermal patch or placebo for two sequential cycles of chemotherapy. Patients' severity of diarrhoea was physician-assessed using NCI grade of diarrhoea and patient-assessed using information recorded in daily diaries of bowel movements.

Results: Overall AGI004 doubled the odds of a response to treatment on the first day of chemotherapy based on physician assessment of NCI grade of diarrhoea compared with placebo (odds ratio = 2.0, 90% confidence interval: 0.9-4.5) and there was a trend to improved response rates for AGI004 for the full treatment cycle although these results were not statistically significant. There was also evidence of significantly improved response rates based on patient assessment of diarrhoea both overall (P = 0.05) and at the 8-mg dose level (P = 0.02) compared with placebo.

Conclusion: AGI004 demonstrated effectiveness in reducing chemotherapy-associated diarrhoea, with results suggesting response across multiple measurements of diarrhoea. Treatment was well tolerated with no drug-related adverse events. Further evaluation of this agent in the management of CID is warranted.

Original languageEnglish
Pages (from-to)1027-1033
Number of pages7
JournalBritish Journal of Cancer
Volume108
Issue number5
DOIs
Publication statusPublished - 19 Mar 2013

Keywords

  • METASTATIC COLORECTAL-CANCER
  • MECAMYLAMINE
  • TRIAL
  • ACTIVATED-CHARCOAL
  • OCTREOTIDE
  • diarrhoea
  • FLUOROURACIL
  • chemotherapy
  • LEUCOVORIN
  • IRINOTECAN-INDUCED DIARRHEA
  • STOOL FORM
  • PREVENTION
  • symptom control

Fingerprint Dive into the research topics of 'A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea'. Together they form a unique fingerprint.

Cite this